Future strategies for the treatment of diastolic heart failure

References

• Vasan R. S., Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000; 101: 2118–21
   PubMed Web of Science ®Google Scholar
• Senni M., Redfield M. M. Heart failure with preserved systolic function. A different natural history?. J Am Coll Cardiol 2001; 38: 1277–82
   PubMedGoogle Scholar
• Vasan R. S., Larson M. G., Benjamin E. J., Evans J. C., Reiss C. K., Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population‐based cohort. J Am Coll Cardiol 1999; 33: 1948–55
   PubMed Web of Science ®Google Scholar
• Tsutsui H., Tsuchihashi M., Takeshita A. Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 2001; 88: 530–3
   PubMed Web of Science ®Google Scholar
• Brutsaert D. L., Sys S. U., Gillebert T. C. Diastolic failure: pathophysiology and therapeutic implications. J Am Coll Cardiol 1993; 22: 318–25
   PubMed Web of Science ®Google Scholar
• Grossman W. Diastolic dysfunction and congestive heart failure. Circulation 1990; 81((2 Suppl))III1–III7
   PubMedGoogle Scholar
• Borbely A., van d V., Papp Z., Bronzwaer J. G., Edes I., Stienen G. J., et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005; 111: 774–81
   PubMed Web of Science ®Google Scholar
• Kass D. A., Bronzwaer J. G., Paulus W. J. What mechanisms underlie diastolic dysfunction in heart failure?. Circ Res 2004; 94: 1533–42
   PubMed Web of Science ®Google Scholar
• Sweitzer N. K., Stevenson L. W. Diastolic heart failure: miles to go before we sleep. Am J Med 2000; 109((8))683–5
   PubMedGoogle Scholar
• Opie L. H. The heart physiology, from cell to circulation. Lippincott‐Raven publishers, Philadelphia 1998, Third edition ed
   Google Scholar
• Kitzman D. W., Higginbotham M. B., Cobb F. R., Sheikh K. H., Sullivan M. J. Exercise intolerance in patients with heart failurevand preserved left ventricular systolic function: failure of the Frank‐Starling mechanism. J Am Coll Cardiol 1991; 17: 1065–72
   PubMed Web of Science ®Google Scholar
• Little W. C., Wesley‐Farrington D. J., Hoyle J., Brucks S., Robertson S., Kitzman D. W., et al. Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunction. J Cardiovasc Pharmacol 2004; 43: 288–93
   PubMed Web of Science ®Google Scholar
• Little W. C. Hypertensive pulmonary oedema is due to diastolic dysfunction. Eur Heart J 2001; 22: 1961–4
   PubMedGoogle Scholar
• Zile M. R., Baicu C. F., Gaasch W. H. Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953–9
   PubMed Web of Science ®Google Scholar
• Zile M. R., Brutsaert D. L. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002; 105: 1503–8
   PubMed Web of Science ®Google Scholar
• Fukuda N., Sasaki D., Ishiwata S., Kurihara S. Length dependence of tension generation in rat skinned cardiac muscle: role of titin in the Frank‐Starling mechanism of the heart. Circulation 2001; 104: 1639–45
   PubMed Web of Science ®Google Scholar
• Yamamoto K., Masuyama T., Sakata Y., Nishikawa N., Mano T., Yoshida J., et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002; 55: 76–82
   PubMed Web of Science ®Google Scholar
• Hogg K., McMurray J. Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis 2005; 47: 357–66
   PubMedGoogle Scholar
• Benedict C. R., Weiner D. H., Johnstone D. E., Bourassa M. G., Ghali J. K., Nicklas J., et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. J Am Coll Cardiol 1993, (4 Suppl. A): 146A–53A
   Google Scholar
• Kitzman D. W., Little W. C., Brubaker P. H., Anderson R. T., Hundley W. G., Marburger C. T., et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288: 2144–50
   PubMed Web of Science ®Google Scholar
• Yamaguchi H., Yoshida J., Yamamoto K., Sakata Y., Mano T., Akehi N., et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 55–60
   PubMed Web of Science ®Google Scholar
• Asif M., Egan J., Vasan S., Jyothirmayi G. N., Masurekar M. R., Lopez S., et al. An advanced glycation endproduct cross‐link breaker can reverse age‐related increases in myocardial stiffness. Proc Natl Acad Sci USA 2000; 97: 2809–13
   PubMed Web of Science ®Google Scholar
• Hunt S. A., Baker D. W., Chin M. H., Cinquegrani M. P., Feldman A. M., Francis G. S., et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001; 104: 2996–3007
   PubMed Web of Science ®Google Scholar
• Vasan R. S., Benjamin E. J. Diastolic heart failure—No time to relax. N Engl J Med 2001; 344: 56–9
   PubMedGoogle Scholar
• Hunt S. A., Abraham W. T., Chin M. H., Feldman A. M., Francis G. S., Ganiats T. G., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult‐Summary Article A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: 1116–43
   Web of Science ®Google Scholar
• Solomon S. D., Wang D., Finn P., Skali H., Zornoff L., McMurray J. J., et al. Effect of candesartan on cause‐specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004; 110: 2180–3
   PubMed Web of Science ®Google Scholar
• Carson P., Massie B. M., McKelvie R., McMurray J., Komajda M., Zile M., et al. The irbesartan in heart failure with preserved systolic function (I‐PRESERVE) trial: rationale and design. J Card Fail 2005; 11: 576–85
   PubMed Web of Science ®Google Scholar
• Effects of enalapril on mortality in severe congestive heart failure, Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429–35
   PubMed Web of Science ®Google Scholar
• Carson P., Johnson G., Fletcher R., Cohn J. Mild systolic dysfunction in heart failure (left ventricular ejection fraction>35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V‐HeFT). J Am Coll Cardiol 1996; 27: 642–9
   PubMed Web of Science ®Google Scholar
• Antony I., Lerebours G., Nitenberg A. Angiotensin‐converting enzyme inhibition restores flow‐dependent and cold pressor test‐induced dilations in coronary arteries of hypertensive patients. Circulation 1996; 94: 3115–22
   PubMed Web of Science ®Google Scholar
• Drexler H., Kurz S., Jeserich M., Munzel T., Hornig B. Effect of chronic angiotensin‐converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am J Cardiol 1995; 76: 13E–8E
   Google Scholar
• Kool M. J., Lustermans F. A., Breed J. G., Struyker Boudier H. A., Hoeks A. P., Reneman R. S., et al. The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J Hypertens 1995; 13: 839–48
   PubMed Web of Science ®Google Scholar
• London G. M., Pannier B., Guerin A. P., Marchais S. J., Safar M. E., Cuche J. L. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end‐stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90: 2786–96
   PubMed Web of Science ®Google Scholar
• Nakashima M., Mombouli J. V., Taylor A. A., Vanhoutte P. M. Endothelium‐dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest 1993; 92: 2867–71
   PubMed Web of Science ®Google Scholar
• Thybo N. K., Stephens N., Cooper A., Aalkjaer C., Heagerty A. M., Mulvany M. J. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25: 474–81
   PubMed Web of Science ®Google Scholar
• Cleland J. G., Tendera M., Adamus J., Freemantle N., Gray C. S., Lye M., et al. Perindopril for elderly people with chronic heart failure: the PEP‐CHF study. The PEP investigators. Eur J Heart Fail 1999; 1: 211–7
   PubMed Web of Science ®Google Scholar
• Brilla C. G., Matsubara L. S., Weber K. T. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A–6A
   PubMed Web of Science ®Google Scholar
• Roongsritong C., Sutthiwan P., Bradley J., Simoni J., Power S., Meyerrose G. E. Spironolactone improves diastolic function in the elderly. Clin Cardiol 2005; 28: 484–7
   PubMed Web of Science ®Google Scholar
• Bergstrom A., Andersson B., Edner M., Nylander E., Persson H., Dahlstrom U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler‐echocardiographic study (SWEDIC). Eur J Heart Fail 2004; 6: 453–61
   PubMed Web of Science ®Google Scholar
• Takeda Y., Fukutomi T., Suzuki S., Yamamoto K., Ogata M., Kondo H., et al. Effects of carvedilol on plasma B‐type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 2004; 94: 448–53
   PubMed Web of Science ®Google Scholar
• The effect of digoxin on mortality and morbidity in patients with heart failure, The Digitalis Investigation Group. N Engl J Med 1997; 336: 525–33
   PubMed Web of Science ®Google Scholar
• van Kraaij D. J., Jansen R. W., Bouwels L. H., Gribnau F. W., Hoefnagels W. H. Furosemide withdrawal in elderly heart failure patients with preserved left ventricular systolic function. Am J Cardiol 2000; 85: 1461–6
   PubMed Web of Science ®Google Scholar
• Ulrich P., Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1–21
   PubMedGoogle Scholar
• Vasan S., Zhang X., Zhang X., Kapurniotu A., Bernhagen J., Teichberg S., et al. An agent cleaving glucose‐derived protein crosslinks in vitro and in vivo. Nature 1996; 382: 275–8
   PubMed Web of Science ®Google Scholar
• Bakris G. L., Bank A. J., Kass D. A., Neutel J. M., Preston R. A., Oparil S. Advanced glycation end‐product cross‐link breakers: a novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004; 17: 23S–30S
   PubMed Web of Science ®Google Scholar
• Candido R., Forbes J. M., Thomas M. C., Thallas V., Dean R. G., Burns W. C., et al. A breaker of advanced glycation end products attenuates diabetes‐induced myocardial structural changes. Circ Res 2003; 92: 785–92
   PubMed Web of Science ®Google Scholar
• Vaitkevicius P. V., Lane M., Spurgeon H., Ingram D. K., Roth G. S., Egan J. J., et al. A cross‐link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci USA 2001; 98: 1171–5
   PubMed Web of Science ®Google Scholar
• Little W. C., Zile M. R., Kitzman D. W., Hundley W. G., O'Brien T. X., Degroof R. C. The Effect of Alagebrium Chloride (ALT‐711), a Novel Glucose Cross‐Link Breaker, in the Treatment of Elderly Patients With Diastolic Heart Failure. J Card Fail 2005; 11: 191–5
   PubMed Web of Science ®Google Scholar
• Satoh N., Sato T., Shimada M., Yamada K., Kitada Y. Lusitropic effect of MCC‐135 is associated with improvement of sarcoplasmic reticulum function in ventricular muscles of rats with diabetic cardiomyopathy. J Pharmacol Exp Ther 2001; 298: 1161–6
   PubMedGoogle Scholar
• Zile M., Gaasch W., Little W., Francis G., Tavazzi L., Cleland J., et al. A phase II, double‐blind, randomized, placebo‐controlled, dose comparative study of the efficacy, tolerability, and safety of MCC‐135 in subjects with chronic heart failure, NYHA class II/III (MCC‐135‐GO1 study): rationale and design. J Card Fail 2004; 10: 193–199
   PubMedGoogle Scholar
• Rose E. A., Gelijns A. C., Moskowitz A. J., Heitjan D. F., Stevenson L. W., Dembitsky W., et al. Long‐term mechanical left ventricular assistance for end‐stage heart failure. N Engl J Med 2001; 345: 1435–43
   PubMed Web of Science ®Google Scholar
• Abraham W. T., Fisher W. G., Smith A. L., Delurgio D. B., Leon A. R., Loh E., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845–53
   PubMed Web of Science ®Google Scholar
• Sabbah H. N. The cardiac support device and the myosplint: treating heart failure by targeting left ventricular size and shape. Ann Thorac Surg 2003; 75((6 Suppl.))S13–9
   Google Scholar
• Landesberg A., Konyukhov E., Shofti R., Vaknin Y., Shenhav A., Livshitz L., et al. Augmentation of dilated failing left ventricular stroke work by a physiological cardiac assist device. Ann N Y Acad Sci 2004; 1015: 379–90
   PubMedGoogle Scholar
• del Monte F., Harding S. E., Dec G. W., Gwathmey J. K., Hajjar R. J. Targeting phospholamban by gene transfer in human heart failure. Circulation 2002; 105: 904–7
   PubMed Web of Science ®Google Scholar
• Frank K. F., Bolck B., Brixius K., Kranias E. G., Schwinger R. H. Modulation of SERCA: implications for the failing human heart. Basic Res Cardiol 2002; 97((Suppl. 1))I72–8
   Google Scholar
• Hasenfuss G., Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol 2002; 34: 951–69
   PubMed Web of Science ®Google Scholar
• MacLennan D. H., Kranias E. G. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003; 4: 566–77
   PubMed Web of Science ®Google Scholar
• Schwartz K., Mercadier J. J. Molecular and cellular biology of heart failure. Curr Opin Cardiol 1996; 11: 227–36
   PubMedGoogle Scholar
• Miyamoto M. I., del Monte F., Schmidt U., DiSalvo T. S., Kang Z. B., Matsui T., et al. Adenoviral gene transfer of SERCA2a improves left‐ventricular function in aortic‐banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000; 97: 793–8
   PubMed Web of Science ®Google Scholar
• Schmidt U., del Monte F., Miyamoto M. I., Matsui T., Gwathmey J. K., Rosenzweig A., et al. Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)‐ATPase. Circulation 2000; 101: 790–6
   PubMed Web of Science ®Google Scholar
• Hoshijima M., Ikeda Y., Iwanaga Y., Minamisawa S., Date M. O., Gu Y., et al. Chronic suppression of heart‐failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002; 8: 864–71
   PubMed Web of Science ®Google Scholar
• Schmidt U., Zhu X., Lebeche D., Huq F., Guerrero J. L., Hajjar R. J. In vivo gene transfer of parvalbumin improves diastolic function in aged rat hearts. Cardiovasc Res 2005; 66: 318–23
   PubMedGoogle Scholar
• Hutcheson K. A., Atkins B. Z., Hueman M. T., Hopkins M. B., Glower D. D., Taylor D. A. Comparison of benefits on myocardial performance of cellular cardiomyoplasty with skeletal myoblasts and fibroblasts. Cell Transplant 2000; 9: 359–68
   PubMed Web of Science ®Google Scholar